Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Community
/
United States
/
Pharmaceuticals & Biotech
/
Aurinia Pharmaceuticals
AUPH
Aurinia Pharmaceuticals
Aging Demographics And LUPKYNIS Uptake Will Expand Markets
AN
AnalystHighTarget
Not Invested
Consensus Narrative from 7 Analysts
Published
23 Aug 25
Updated
23 Aug 25
0
Set Fair Value
0
votes
Share
AnalystHighTarget
's Fair Value
US$16.46
26.3% undervalued
intrinsic discount
23 Aug
US$12.14
1Y
80.8%
7D
-0.7%
Loading
1Y
80.8%
7D
-0.7%
Author's Valuation
US$16.5
26.3% undervalued
intrinsic discount
AnalystHighTarget Fair Value
View Valuation
Narrative
Updates
0
Valuator
Company Info
Notes
AnalystHighTarget Fair Value
US$16.5
26.3% undervalued
intrinsic discount
Future estimation in
3 Years
time period
Past
Future
-156m
480m
2014
2017
2020
2023
2025
2026
2028
Revenue US$479.9m
Earnings US$253.1m
Revenue
Profit Margin
Future PE
Revenue
% p.a.
0
Decrease
Increase
Current revenue growth rate
11.91%
Biotech revenue growth rate
11.91%
Other Inputs & Calculation
Risk Level (Discount Rate)
Our default considers factors like the company's size, volatility, profitablity and country of operation.
Risk Level (Discount Rate)
%
0
Decrease
Increase
Current discount rate
6.45%
Calculation
US$253.12m
Earnings '28
x
8.24x
PE Ratio '28
=
US$2.08b
Market Cap '28
US$2.08b
Market Cap '28
/
105.88m
No. shares '28
=
US$19.69
Share Price '28
US$19.69
Share Price '28
Discounted to 2025 @ 6.45% p.a.
=
US$16.32
Fair Value '25